NIH NIAID Emergency Awards: Rapid Investigation PAR-20-178

National institution of health (NIH) National Institute of Allergy and Infectious Diseases (NIAID)- Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 – PAR-20-178

Subsidy: no limit

Deadline: Applications will be accepted on a rolling basis, beginning on 30 April 2020.

Consortium: Both US and non-US for profit and non-profit organizations can apply.

Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines, and more.

Go to the NIH NIAID website

The subsidy landscape is responding quickly to the COVID-19 virus and the problems this crisis causes world-wide. A lot of new funding opportunities are being released to assist researchers and companies with their Research and Development activities against COVID-19. We have made an overview of all COVID-19 grants & funding opportunities. Check our COVID-19 Call Overview and stay up-to-date.

A more detailed and tailor-made overviews are available in 3 different products:

1. Funding Scan. A summarized overview of funding opportunities for one specific R&D project with a short profile of the researcher or company. This includes a strategy with upcoming funding opportunities for the next year.
2. Funding Advice. A detailed description of your company, research group, R&D projects and an overview of the timelines involved in future development. This includes a funding strategy for each project for the next 2 years.
3. Funding Plan. A long-term funding strategy taking into consideration multiple R&D pillars. This detailed strategy focuses on multiple sources of funding and addresses financial weaknesses in continuing strategic planning.

Read more about it on our Strategic Funding Advice page.